The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model

NPM-ALK(+) T-cell anaplastic large-cell lymphoma (ALCL) is an aggressive type of cancer. Standard treatment of NPM-ALK(+) ALCL is CHOP polychemotherapy. Although patients initially respond favorably to CHOP, resistance, relapse, and death frequently occur. Recently, selective targeting of ALK has em...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Suraj Konnath, Vishwamitra, Deeksha, Manshouri, Roxsan, Shi, Ping, Amin, Hesham M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170597/
https://www.ncbi.nlm.nih.gov/pubmed/25026277

Ejemplares similares

Ejemplares similares